RxDoctor Payments Data

Luke Chang, MD

Ophthalmology · Annapolis, MDNPI 1497287031

Payments from drug & device makers

$6,913in general payments, 2019–2025

Across 136 payments — averaging $50.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • AbbVie$1K
  • Alcon$620
  • NEW World Medical,inc.$610
  • Glaukos Corporation$313
  • Tarsus Pharmaceuticals, Inc.$290
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$2,25733%
  • Food & beverage$4,65667%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,913 in reported general payments places this provider in the 80th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$583,733
Medicare patients
966
Services billed
6,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate143$83,387
LumiganBimatoprost101$61,603
RocklatanNetarsudil Mesylat/Latanoprost58$48,122
RestasisCyclosporine12$21,923
SimbrinzaBrinzolamide/Brimonidine Tart47$18,825
CombiganBrimonidine Tartrate/Timolol36$18,088
Brimonidine Tartrate470$16,000
VyzultaLatanoprostene Bunod17$13,627
Latanoprost735$12,334
Timolol Maleate387$10,150
Prednisolone Acetate135$8,083
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat317$7,835
Timolol MaleateTimolol Maleate/Pf13$6,144
Dorzolamide Hcl237$5,677
Travoprost26$5,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,445$101,614149 claims
AlconSimbrinza$620$18,82547 claims
Bausch & Lomb Americas Inc.Vyzulta$71$13,62717 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$2,174$3,13715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →